(Q31401240)

2 July 2017

1 reference

title

The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors (English)

1 reference

2 July 2017

Sintchak MD

1

1 reference

2 July 2017

Nimmesgern E

series ordinal

2

1 reference

2 July 2017

language of work or name

1 reference

1 May 2000

1 reference

2 July 2017

1 reference

2 July 2017

volume

47

1 reference

2 July 2017

issue

2-3

1 reference

2 July 2017

page(s)

163-184

1 reference

Mycophenolate mofetil and its mechanisms of action

2 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Structure-based drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Synthesis and modeling studies with monocyclic analogues of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Probing the active site of human IMP dehydrogenase using halogenated purine riboside 5'-monophosphates and covalent modification reagents

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

The structure of a domain common to archaebacteria and the homocystinuria disease protein

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

A fast and efficient method for 2D and 3D molecular shape description

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

In vitro effects of mycophenolic acid and allopurinol against Leishmania tropica in human macrophages

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Clinical pharmacokinetics of mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Mycophenolic Acid: an Anti-cancer Compound with Unusual Properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Crystal structure of human type II inosine monophosphate dehydrogenase: implications for ligand binding and drug design

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

The conversion of 2-β-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Lymphocyte-Selective Cytostatic and Immunosuppressive Effects of Mycophenolic Acid in Vitro: Role of Deoxyguanosine Nucleotide Depletion

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5'-monophosphate dehydrogenase.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Inhibition of IMPDH by mycophenolic acid: dissection of forward and reverse pathways using capillary electrophoresis

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

The inhibition of nucleic acid synthesis by mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Pharmacodynamics of the inhibition of GTP synthesis in vivo by mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Mycophenolic acid and thiazole adenine dinucleotide inhibition of Tritrichomonas foetus inosine 5'-monophosphate dehydrogenase: implications on enzyme mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Leflunomide: an immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Human IMP dehydrogenase. Kinetics and regulatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Identification of the IMP binding site in the IMP dehydrogenase from Tritrichomonas foetus.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

IMP dehydrogenase, an enzyme linked with proliferation and malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

A BLINDED, RANDOMIZED CLINICAL TRIAL OF MYCOPHENOLATE MOFETIL FOR THE PREVENTION OF ACUTE REJECTION IN CADAVERIC RENAL TRANSPLANTATION1

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

A geometric approach to macromolecule-ligand interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Dual inhibitory effect of bredinin

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Synthesis of a methylenebis(phosphonate) analogue of mycophenolic adenine dinucleotide: a glucuronidation-resistant MAD analogue of NAD.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

FK506 and ciclosporin: molecular probes for studying intracellular signal transduction

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Mechanisms of action of cyclosporine.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Immunosuppressive effect of mycophenolic acid.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Studies on bredinin. I. Isolation, characterization and biological properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Human type I and II IMP dehydrogenases as drug targets

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Protein-drug complexes important for immunoregulation and organ transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Synthesis and immunosuppressive activity of some side-chain variants of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Structure-activity relationships for inhibition of inosine monophosphate dehydrogenase by nuclear variants of mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Conformational changes and stabilization of inosine 5'-monophosphate dehydrogenase associated with ligand binding and inhibition by mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Biochemical analysis of the modular enzyme inosine 5'-monophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Pharmacology of immunosuppressive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

The conformation of NADH bound to inosine 5'-monophosphate dehydrogenase determined by transferred nuclear Overhauser effect spectroscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Immunophilin-sensitive protein phosphatase action in cell signaling pathways

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Rediscovering mycophenolic acid: A review of its mechanism, side effects, and potential uses

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Structure and mechanism of inosine monophosphate dehydrogenase in complex with the immunosuppressant mycophenolic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Mechanism of action of 1- -D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Immunosuppressants: cellular and molecular mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Tiazofurin: biological effects and clinical uses

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Purification, characterization, and kinetic analysis of inosine 5'-monophosphate dehydrogenase of Tritrichomonas foetus

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Differential effects of inhibitors of purine metabolism on two trichomonad species

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Inactivation of inosine 5'-monophosphate dehydrogenase by the antiviral agent 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide 5'-monophosphate

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Kinetic mechanism of human inosine 5'-monophosphate dehydrogenase type II: random addition of substrates and ordered release of products

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

A potent "fat base" nucleotide inhibitor of IMP dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Crystal structure of Tritrichomonas foetus inosine-5'-monophosphate dehydrogenase and the enzyme-product complex

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Mycophenolic acid: antiviral and antitumor properties

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Monovalent cation activation and kinetic mechanism of inosine 5'-monophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

Characteristics and crystal structure of bacterial inosine-5'-monophosphate dehydrogenase

1 reference

https://api.crossref.org/works/10.1016%2FS0162-3109%2800%2900193-4

7 January 2021

10.1016/S0162-3109(00)00193-4

Identifiers

DOI

1 reference

2 July 2017

1 reference